Constitutive p53 heightens mitochondrial apoptotic priming and favors cell death induction by BH3 mimetic inhibitors of BCL-xL

J Le Pen¹, M Laurent¹, K Sarosiek², C Vuillier¹, F Gautier¹,³, S Montessuit⁴, J-C Martinou⁴, A Letai², F Braun*¹,⁵ and PP Juin*¹,³

Proapoptotic molecules directly targeting the BCL-2 family network are promising anticancer therapeutics, but an understanding of the cellular stress signals that render them effective is still elusive. We show here that the tumor suppressor p53, at least in part by transcription independent mechanisms, contributes to cell death induction and full activation of BAX by BH3 mimetic inhibitors of BCL-xL. In addition to mildly facilitating the ability of compounds to derepress BAX from BCL-xL, p53 also provides a death signal downstream of anti-apoptotic proteins inhibition. This death signal cooperates with BH3-induced activation of BAX and it is independent from PUMA, as enhanced p53 can substitute for PUMA to promote BAX activation in response to BH3 mimetics. The acute sensitivity of mitochondrial priming to p53 revealed here is likely to be critical for the clinical use of BH3 mimetics.

Cell Death and Disease (2016) 7, e2083; doi:10.1038/cddis.2015.400; published online 4 February 2016
dividing cancer cells, promotes death signals that critically cooperate with BH3 mimetic trigger to cell death.

Results

Constitutive expression of p53 in HCT116 p21 −/− cells contributes to induction of cell death by the BCL-2/BCL-xL inhibitor ABT-737. We have previously established that the colorectal cancer HCT116 p21 −/− cell line is a model cell line that requires sustained inhibition of PUMA and BAX by BCL-xL to survive. This cell line is therefore a useful model to study the mechanisms leading to BAX-dependent cell death following BH3 mimetic inhibition of BCL-xL.13 Independently from p21 loss, the HCT116 p21 −/− cells were shown to express constitutively high levels of p5329 (see also Figure 1a).

These cells are more sensitive than the parental (HCT116 wt) cell line to treatment with the BH3 mimetic inhibitor of BCL-2 and BCL-xL, ABT-737 (Figure 1b). Whereas down regulation of p21 by RNA interference in wild-type cells has no detectable impact on their resistance to ABT-737 (Figure 1c), downregulation of p53 in p21 null cells by a lentiviral-based shRNA significantly decreased their sensitivity (Figure 1d). Reciprocally, treatment of HCT116 wt mice with the Mouse double minute 2 homolog (Mdm2) inhibitor Nutlin-3a enhanced p53 expression and the response to ABT-737 (Figure 1e) whereas HCT116 p53 −/− cells remained resistant to the combined treatment (data not shown). This effect was inhibited by down regulation of p53 (Figure 1f). Of note, p21 levels were induced by Nutlin-3a treatment in these assays, further underscoring the consequent role of p21 expression on sensitivity to ABT-737 (Supplementary Figure S1A). Similar results were observed in the breast cancer Cal51 cell lines where ABT-737 and Nutlin-3a treatment synergized to induce p53-dependent cell death (Supplementary Figure S1B–C).

Altogether, these results show that p53, when expressed above a certain threshold, contributes to the apoptotic response induced by ABT-737.

p53 does not sensitize cells to ABT-737 through transcriptional induction of NOXA, PUMA or BAX. PUMA and BAX are major actors of the apoptotic response of HCT116 p21 −/− cells to ABT-737, whereas BIM did not appear to contribute to these responses.13 Moreover, silencing of NOXA expression prevented cell death induced by ABT-737 (Figure 2a), indicating that this endogenous MCL-1 inhibitor has a role in cell death induction by BCL-2/BCL-xL inhibition. As NOXA, PUMA and BAX are transcriptional targets of activated p53,30 we investigated whether their constitutive induction by p53 prior treatment, and/or their induction by p53 during treatment, had a role.

NOXA expression was increased in HCT116 p21 −/− upon ABT-737 treatment (Figure 2a), as reported in other cell lines.17,31 Such induction was still detectable in p53-depleted cells (Figure 2b) and overexpression of NOXA in HCT116 p53-null cells neither induced cell death by itself nor sensitized
them to ABT-737 treatment (Figure 2c). This argues that NOXA is an inducible actor of ABT-737-triggered apoptosis. However its induction does not absolutely require p53 and it is insufficient per se, in the absence of p53, to induce efficient cell death in combination with ABT-737.

The situation was different for PUMA and BAX. Indeed, investigation of kinetic changes in PUMA and BAX protein and mRNA expression levels during ABT-737 treatment brought no support to the hypothesis that their expression was induced at all (and a fortiori by p53) during treatment (Figure 3a).

Moreover, PUMA and BAX were not detectably affected by silencing of p53 in HCT116 p21−/− cells, whether these were untreated or treated 24 h with ABT-737 (Figure 1d). Indeed, ABT-737 had no effect on the expression of p53 itself in the p21−/− cells (Figure 3b) and the transcriptional activity of p53, as measured in a luciferase reporter assay, was...
not detectably modified by ABT-737 treatment in p21-null cells (Figure 3c). Importantly, neither Pifitrin-α (an inhibitor of p53-dependent transcriptional activation), nor α-Amanitin (an inhibitor of RNA polymerase-mediated transcription) inhibited cell death induced by ABT-737 in HCT116 p21−/− cells (Figure 3d) arguing that the transcriptional activity of p53 is dispensable for cell death induction by ABT-737 in these cells. Notably, we even noted a stimulatory effect of these compounds. This evokes a preceding publication who ascribed this enhancement to the fact that p53 transcriptional activity is not only dispensable for apoptotic responses, but also a restraint to the execution of p53 mitochondrial death program. Pretreatment with Pifitrin-α of the wild-type cells did not decrease cell death induced by the combined ABT-737 and Nutlin-3a treatment, indicating that the transcriptional activity of p53 is dispensable under these conditions (Supplementary Figure S1D).

Finally, it should be noted that the effects exerted by p53 are not functionally equivalent to those of the BH3-only proteins NOXA and/or PUMA. As shown below, p53 exerts apoptotic effects even in cells depleted of MCL-1 and thus they cannot solely rely on the induction of NOXA (which essentially functions as an inhibitor of MCL-1) or of NOXA-like molecules. Moreover, we found that in HCT116 p21−/− PUMA−/− cells, enhancement of p53 expression by Nutlin-3a treatment sensitized these otherwise resistant cells to ABT-737 treatment (Figure 4a and b). Cell death induced under these conditions was inhibited by silencing of p53 by RNA interference (Figure 4a) and by pretreatment with a broad-spectrum caspase inhibitor Q-VD-OPh (Figure 4b), whereas pretreatment with Pifitrin-α did not decrease the level of cell death (Supplementary Figure S1D).

Our data support the notion that p53 exerts an effect that adds to these of NOXA and PUMA to promote cell death in ABT-737 cells, and that this effect is in great part independent of its transcriptional activity.

p53 favors BAX activation in ABT-737-treated cells. As BAX has a major role in cell death induced by ABT-737 treatment or BCL-xL loss in HCT116 p21−/− cells,13 we investigated the influence of p53 on BAX ‘activation’ by ABT-737 treatment.

We first evaluated conformation changes in the amino-terminus domain of BAX by immunoprecipitation assays with the 6A7 antibody. 6A7 immunoreactive forms of BAX were detected in ABT-737-treated p21-null cells, but only weakly in wild-type cells and not in p53-null cells, indicating that the insensitivity of the wild-type and p53-null cells coincides with an absence of efficient activation of BAX (Figure 5a). The induction of the 6A7 positive form was severely impaired in p21-null cells depleted in p53 arguing that p53 favors conformation change amplitudes of BAX in response to ABT-737 (Figure 5a). Importantly, even though PUMA is a major driver of BAX ‘activation’ in ABT-737 treated HCT116 p21−/− cells, a significant conformation change in BAX was detected in HCT116 p21−/− PUMA−/− cells treated by the combination ABT-737/Nutlin3a (Figure 5b). This implies that enhanced p53 can substitute for PUMA to promote BAX activation and subsequent cell death (as shown in Figure 4).

Other features of BAX activation are mitochondrial translocation and oligomerization. To evaluate BAX mitochondrial translocation, percentages of cells with punctate BAX staining were determined after ABT-737 treatment (Figure 5c and Supplementary Figure S2). ABT-737 showed a punctate staining pattern that colocalized with a mitochondrial marker upon ABT-737 treatment in p21-null cells but not in cells infected with a p53 shRNA lentivirus (Figure 5c). No translocation of BAX was observed in the wild-type cells and in p53-null cells, consistent with the absence of 6A7-positive BAX molecules in these cells (Figure 5c). In agreement with data above, oligomerization of BAX, assessed by crosslinking with disuccinimidyl suberate (DSS) was detected in ABT-737-treated p21-null cells, but only weakly in wild-type cells and not in p53-null cells. This oligomerization of BAX in ABT-737 treated HCT116 p21-null cells was abolished by silencing of p53 (Figure 5d).

p53 modulates both the inhibition of BCL-xL by ABT-737 and death signals downstream of BCL-xL. BAX activation is critically kept in check by the BH3-binding activity of BCL-xL in HCT116 p21−/− cells, as shown by the fact that inhibition of BCL-2/BCL-xL by ABT-737, and BCL-xL down regulation, both trigger BAX-dependent cell death.13 In further support to this, treatment of these cells with...
p53 favors BAX activation upon ABT-737 treatment. (a) HCT116 wt, p53−/−, p21−/−, or p21−/− previously infected with control or p53 shRNAs were treated for 16 h by 2 μM ABT-737, before immunoprecipitation using a conformation specific-BAX antibody (6A7) and a non-conformation specific BAX antibody (BAX tot.) (b) HCT116 p21−/−, PUMA−/− were treated for 20 h by 2 μM ABT-737 and/or 10 μM Nutlin3a, before immunoprecipitation using the indicated anti-BAX antibodies. (c) HCT116 wt, p53−/−, p21−/−, or p21−/− previously infected with control or p53 shRNAs were treated for 20 h by 2 μM ABT-737. Cells were stained using Mitotracker Red, and a BAX antibody. More than 50 cells were observed per treatment and cells exhibiting punctate BAX staining were counted. (d) HCT116 wt, p53−/−, p21−/−, or p21−/− previously infected with control or p53 shRNAs were treated for 16 h by 2 μM ABT-737. Hundred micrograms of proteins were crosslinked by DSS before western blot analysis. (*) (**): sizes in agreement with BAX oligomers. Data presented are mean ± S.E.M. of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001.

Figure 5  p53 favors BAX activation upon ABT-737 treatment. (a) HCT116 wt, p53−/−, p21−/−, or p21−/− previously infected with control or p53 shRNAs were treated for 16h by 2μM ABT-737, before immunoprecipitation using a conformation specific-BAX antibody (6A7) and a non-conformation specific BAX antibody (BAX tot.) (b) HCT116 p21−/−, PUMA−/− were treated for 20h by 2μM ABT-737 and/or 10μM Nutlin3a, before immunoprecipitation using the indicated anti-BAX antibodies. (c) HCT116 wt, p53−/−, p21−/−, or p21−/− previously infected with control or p53 shRNAs were treated for 20h by 2μM ABT-737. Cells were stained using Mitotracker Red, and a BAX antibody. More than 50 cells were observed per treatment and cells exhibiting punctate BAX staining were counted. (d) HCT116 wt, p53−/−, p21−/−, or p21−/− previously infected with control or p53 shRNAs were treated for 16h by 2μM ABT-737. Hundred micrograms of proteins were crosslinked by DSS before western blot analysis. (*) (**): sizes in agreement with BAX oligomers. Data presented are mean ± S.E.M. of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001.

WEHI-539, a selective BCL-xL inhibitor, triggered p53-dependent cell death (Supplementary Figure S3). This indicates that p53 acts by favoring derepression of BCL-xL sensitive death signals by BH3 mimetics and/or by inducing death signals once BCL-xL is inhibited.

To investigate the former, we measured the spacial proximity between transiently transfected Luciferase-fused BAX and YFP-fused BCL-xL by bioluminescence resonance energy transfer (BRET) in live cells expressing p53 or not, treated or not with ABT-737. As previously reported,33 saturable BRET signals were observed between donor BAX and increasing levels of acceptor BCL-xL, indicative of a specific interaction between these proteins. Specificity was further confirmed by assessing that BRET signals were significantly less intense when a variant of YFP-BCL-xL carrying a single point-mutation in the BH3 binding site was used (Supplementary Figure S4). The saturation curves that were observed between BAX and wild-type BCL-xL in control HCT116 p21−/− and in p53-depleted cells were almost identical, suggesting that constitutive p53 does not impact on the propensity of BCL-xL to sequester BAX (Figure 6a). We then investigated the influence p53 might have on the sensitivity of these interactions to ABT-737. The effect of a range of ABT-737 concentrations on BAX/BCL-xL BRET signals in control and p53-deleted cells was evaluated. Silencing of p53 in p21-null cells consistently enhanced the resistance of BAX/BCL-xL interactions (evaluated by BRET) to ABT-737 (Figure 6b), indicating that constitutive p53 sensitizes BAX/BCL-xL interactions to ABT-737. Of note, p53 is not absolutely required for ABT-737 to inhibit BAX/BCL-xL interactions, as comparable inhibitions of BRET signals by concentrations above 1 μM of ABT-737 were measured in p53-proficient and p53-deficient cells. This may explain why we detected no difference in the effects of ABT-737 (used at 2 μM) on endogenous BAX/BCL-xL when we grossly evaluated them by co-immunoprecipitation assays in lysates from treated wild-type and p21−/− HCT116 cells (Supplementary Figure S5).

To evaluate whether p53 might exert an apoptotic effect beyond its modulation of BCL-xL sensitivity to ABT-737, we analyzed whether it would have a role even in cells deleted in BCL-xL. In agreement with previous results,13 silencing of BCL-xL in p21-null cells promoted a more efficient cell death in itself than ABT-737 treatment. This effect was not significantly enhanced by silencing of MCL-1 (Figure 7a), whereas silencing of MCL-1 strongly increased cell death of p21−/−cells treated with ABT-737 (Figure 7b). Silencing of the two antiapoptotic proteins lead to a weak level of cell death of HCT116 wt cells (Figure 7a) that was enhanced by Nutlin3a treatment (Figure 7d). Little cell death was measured in the p53 null cells in all these conditions (Figure 7a and c). Moreover, Pifithrin-α did not inhibit cell death in response to the silencing of BCL-xL and MCL-1 in p21 null cells (Figure 7e). Thus, p53 is required to promote cell death in cells in which the proapoptotic proteins are no more sequestered by the antiapoptotic counterparts, independently from its transcriptional activity.

As a whole, these data indicate that, in order to favor BAX activation and cell death in response to BH3 mimetics, p53 both facilitates derepression of BAX from BCL-xL by the BH3
Figure 6  Effect of p53 on BCL-xL binding to BAX. (a) Donor saturation assay analysis: saturation curves were performed in HCT116 p21−/− cells previously infected with control (black) or p53 shRNAs (blue) using increasing amount of vectors encoding YFP-BCL-xL in the presence of a fixed amount of the vector-encoding Rluc-BAX. BRETratios were measured for every YFP-BCL-xL plasmid concentrations and are plotted as a function of the ratio of total acceptor to donor fluorescence (YFP−BCL-xL/Rluc-BAX). The data were fitted using a nonlinear regression equation assuming a single binding site. (b) Dose–response effect of ABT-737 on BCL-xL/BAX BRET signals. HCT116 p21−/− cells previously infected with control (black) or p53 (blue) shRNAs were transiently transfected with a constant amount of plasmid DNA encoding the donor Rluc-BAX (50 ng) and plasmid DNA encoding the acceptor YFP-BCL-xL (200 ng), treated or not with increasing doses of ABT-737 (from 0.1 to 10 μM). %ΔBRET is plotted as a function of the logarithmic ABT-737 concentrations. The data were fitted using a nonlinear regression. Data shown represent results from one of three separate BRET titration experiments (performed in duplicate) that produced qualitatively similar results.

Figure 7  p53 contributes to efficient cell death induced by silencing of MCL-1 and BCL-xL. (a) HCT116 wt, p53−/− or p21−/− cells were infected with control or MCL-1 shRNAs. Six hours later, cells were infected with control or BCL-xL shRNAs. Twenty-four hours later, cells were washed, and cell death was assessed after forty-eight additional hours. (b) HCT116 wt, p53−/− or p21−/− cells were infected with control or MCL-1 shRNAs. Cells were washed after 24 h, and treated 16 h by 2 μM ABT-737 before cell death analysis. (c) HCT116 p21−/− cells previously infected with control or p53 shRNAs were infected with control or MCL-1 shRNAs. Six hours later, cells were infected with control or BCL-xL shRNAs. Twenty-four hours later, cells were washed, and cell death was assessed after 48 additional hours. (d) HCT116 wt or p53−/− cells were infected with control or MCL-1 shRNAs. Six hours later, cells were infected with control or BCL-xL shRNAs. Twenty-four hours later, cells were washed, and cell death was assessed after 48 additional hours. (e) HCT116 p21−/− cells were infected as in c and 24 h later, cells were washed and treated by 10 μM Nutlin3a for 48 h before cell death analysis. (f) HCT116 p21−/− cells were infected as in c and 24 h later, cells were washed and treated by 40 μM Pifithrin-α (pif-α). Cell death was assessed after 48 additional hours. Data presented are mean ± S.E.M. of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001
mimetics and full-blown BAX activation once BCL-xL is inhibited (or its expression down regulated).

**p53 heightens mitochondrial apoptotic priming.** We inferred from the above results that, in addition to having a specific effect on the response of BAX/BCL-xL interactions to BH3 mimetics, constitutive p53 would exert a promiscuous effect that amplifies mitochondrial damage in response to most (if not all) perturbations of the BCL-2 network. To test this in an integrated manner, we performed BH3 profiling assays. In these assays, we evaluated, as a marker of mitochondrial integrity, the mitochondrial potential of permeabilized HCT116 p21−/− cells (a) or HCT116 p21−/− PUMA−/− cells (b) previously infected with control or p53 shRNAs, stained with the mitochondrial potential sensitive JC1 dye, and treated with a panel of BH3 peptides. Percent depolarization is shown as the area under the curve (AUC) normalized to positive control fully depolarized mitochondria (FCCP). Dimethyl sulfoxide (DMSO) serves as the negative control. Data presented are mean ± S.E.M. of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001

![Figure 8](#) p53 impacts on mitochondrial priming. Mitochondrial depolarization of digitonin-permeabilized HCT116 p21−/− cells (a) or HCT116 p21−/− PUMA−/− cells (b) previously infected with control or p53 shRNAs, stained with the mitochondrial potential sensitive JC1 dye, and treated with a panel of BH3 peptides. Percent depolarization is shown as the area under the curve (AUC) normalized to positive control fully depolarized mitochondria (FCCP). Dimethyl sulfoxide (DMSO) serves as the negative control. Data presented are mean ± S.E.M. of three independent experiments. *P<0.05, **P<0.01 and ***P<0.001

**Discussion**

ABT-737 and its orally available equivalent ABT-263 do not target MCL-1 but inhibit both BCL-2 and BCL-xL. As the latter
is arguably the most potent anti-apoptotic protein of the family and a major contributor to drug resistance, such compounds are likely to have a role to play in a chemotherapeutic setting. The clinical use of BH3 mimetic inhibitors of BCL-xL is, however, limited by their secondary effects, in particular on platelets. Identifying parameters that determine the therapeutic window of these compounds is therefore important. It is thus of particular relevance to report that p53, even when expressed constitutively under conditions where it does not influence the expression of its proapoptotic transcription targets, enhances cell death induced by BCL-xL inhibition. On one hand, this implies that BH3 mimetics may not totally substitute for the lack of an active p53 tumor suppressor in cancer cells. On the other hand, it implies that healthy tissues may be more harmed than anticipated when BCL-xL inhibitors are combined with chemotherapeutic agents that even mildly affect p53.

BH3 mimetics, because they only inhibit selective subsets of antiapoptotic proteins, efficiently induce apoptosis when two types of signals are also present: signals that inhibit other anti-apoptotic proteins (MCL-1 in the case of ABT-737) and signals that trigger BAX activation. Our results are in line with preceding results and underscore that, to the very least in the case of ABT-737 treatment of the cells used here, NOXA contributes to the former signals, and constitutive PUMA to the latter. However, p53 does not promote ABT-737 induction of cell death solely via expression of either one of these two main actors. Indeed, p53 exerts a proapoptotic activity even in MCL-1-depleted cells. Thus, the apoptotic function of p53 extends beyond inhibition of MCL-1 by induction of NOXA. Moreover, p53 was dispensable for ABT-737 treatment to induce expression of NOXA, an effect we recently reported to rely on the pRB/E2F-1 pathway in p53 mutant cells.17 We also found no evidence of a role of p53 in the expression of PUMA in cells where it nevertheless contributes to cell death. The fact that enhancement of p53 expression sensitizes PUMA knock out cells to ABT-737 demonstrates that p53 exerts a BAX-dependent apoptotic effect that is independent from PUMA, even though it might cooperate with it to favor cell death.

That constitutive p53 heightens mitochondrial priming in cooperation with (and not via) BH3-only proteins is particularly well illustrated by BH3 profiling assays. These assays reveal that down regulation of p53 impacts on the mitochondrial response to numerous BH3 peptides, even in cells where this response is lowered by PUMA knock out (which impacts in itself on mitochondrial priming independently from p53). p53 depletion diminishes the response to lower concentrations of activator BH3 peptides but not to higher concentrations. This is mostly consistent with the notion that constitutive p53 provides signals that cooperate with BH3-mediated activation of BAX, and that are dispensable for MOMP to occur when a sufficient amount of activator BH3 molecules are present. In agreement with this, we found that p53 was required for BAX translocation, change of conformation and oligomerization to be fully patent in cells treated with BH3 mimetics, even though all these events can be reproduced in the absence of p53 in cell-free assays.5,13

Another important implication from the BH3 profiling assays is that the effect of p53 on MOMP lies, at least partly, downstream of anti-apoptotic proteins, as p53 depletion confers resistance to induction of MOMP by the highest concentrations of the sensitizers BAD and HRK-BH3 peptides we could test. In further support of this idea, we found that p53 still had an apoptotic role in cells that were depleted in BCL-xL and/or MCL-1. This implies that p53 would exert a promiscuous, positive, effect on BAX activity regardless of the identity of the antiapoptotic proteins that keep this activity in check. Our observations may thus extend to BCL-2 or MCL-1 inhibition. Arguably, the effect of p53 on the sensitivity of BCL-xL/BAX interactions to ABT-737 might appear as an additional effect, as it implies that p53 might have a specific influence on BCL-xL. We cannot formally rule out, however, that it ensues from a single effect on BAX that favors its displacement from BCL-xL in the same time as its activation.

Pretreatments with either Pifithrin-α (or α-Amanitin) did not inhibit cell death induced by ABT-737, or by the silencing of MCL-1 and BCL-xL, which is reminiscent of their lack of inhibitory effect on Nutlin-induced p53-dependent apoptosis in HCT116 cells.32,34 This argues that p53 would exert at least some of its proapoptotic effects by a transcription-independent function.21,23,24,26,27,35–37 Possibly from the cytoplasm where we found p53 to partly reside in the cells used here (data not shown). It is particularly relevant here to recall that the DNA binding domain of p53 can interact with BCL-xL. This interaction is favored by tetramerization of p53 and it influences the BH3 binding activity of BCL-xL even though it does not occur at the BH3 binding site stricto sensu.21,23,24 p53 might also directly activate BAX and or BAK by a similar, yet to be fully characterized, type of interaction.27,28,36,37

A recombinant p53 constructs encompassing residues 79–39338 had no detectable effect on the priming of HCT116 p21−/− cells (whether they had been depleted in p53 by RNA interference or not prior the assays, data not shown). When incubated with mitochondria isolated from BAX/BAX null mouse embryonic fibroblasts, this recombinant p53 did not trigger cytochrome c release by itself, did not activate recombinant BAX, did not enhance the effects of tBID on BAX, and did not derepress the inhibitory effects of BCL-xL (Supplementary Figure S6). Since this construct lacks the N-terminal transcriptional activation region, this brings support to the notion that this latter portion, but not the DNA binding domain per se is involved in BAX activation.39,40 Cle–trans interconversion of Pro47 in this domain by the prolyl isomerase Pin1 was shown recently to enhance p53 induced BAX activation.41 Of note, we could not find evidence of specific interactions between constitutive p53 and either BAX or BCL-xL in co-immunoprecipitations assays in the cells used in this study, and we failed to detect specific BRET signals between ectopic p53 and any of these BCL-2 proteins (data not shown). We thus can not formally rule out that p53, in addition to its direct effects on BAX, might exert other effects on mitochondrial apoptotic priming.

Taken together, our data unravel widespread effects of p53 on mitochondrial priming. Mitochondrial priming may thus acutely respond to the many stresses that stabilize and activate p53. As BH3 profiling assays are quite sensitive to detect such changes, that can occur without any overt activation of a p53 transcriptional program, this underscores their potential as biomarkers predicting cytotoxicity (and BCL-2 dependency).
in a dynamic manner\(^\text{12}\) and the role of mitochondria as a «sounding board» of stress signals. From a clinical standpoint, the preferred sensitivity to BH3 mimetics of cells that express higher levels of p53 implies that BH3 mimetic treatment may skew clonal diversity and counter-select for cells with less (or less responsive) p53. Understanding the mechanistic basis for p53 induced priming, and finding approaches to bypass the consequences of p53 defects on this priming, are therefore required to avoid this bias.

**Material and methods**

**Cell culture.** The Cal51 cell line obtained from ATCC, was grown in RPMI medium. The HCT116 cell lines (parental, p21\(^-\) / - /, p33\(^-\) / - /, and p21\(^-\) / + /, p33\(^-\) / + /) were grown in McCoy’s 5A, kindly provided by Dr. B. Vogelstein (John Hopkins Kimmel Cancer Center, Baltimore, MD, USA). When specified, we used ABT-737 at 2 μM, WEHI-539 at 2 μM, Nutfin-3α at 10 μM (Sigma, St. Louis, MO, USA), Etoposide at 50 μM (Sigma), PⅢF2 at 40 μM (Sigma), α-Amanitin at 10 μM (Sigma), QVD-OPh at 10 μM (R&D System, Minneapolis, MN, USA).

**Plasmids, RNA interferences and recombinant proteins.** Cells were transfected with pDNA3A (as a control vector) or pDNA3-NOXA vector using Lipofectamine2000 (Invitrogen, Carlsbad, CA, USA). Control siRNA or p21 siRNA (Santa-cruz Biotechnologies, Santa Cruz, CA, USA, respectively #44230 and #29427) were transfected using HiPerfect transfection reagent (Qiagen, Valencia, CA, USA). We used the following lentiviruses: PFG2 and PLK1; bacterial Luc2 as control (5′-gtgaccagcgaatactgt-3′); human BCL-xL (5′-AGGATACAGCTGAGATCAG-3′), and human MCL-1 (5′-gaattgctgagctgtgt-3′); p53 and control were from Addgene, Cambridge, MA, USA (respectively #25636 and #8453). Lentivirus were engineered, produced and titrated as previously described.\(^\text{15}\) A multiplicity of infection of three was used, and further experiments were performed 2 days after infection. Cells infected by PLK1 were selected by adding 1 μM/mL of puromycin to the medium, and cells were used during a maximum of 4 weeks.

The recombinant His-tagged full length BAX and caspase-8-cleaved BID (BID) were prepared as previously described.\(^\text{48}\) The recombinant p53 was kindly provided by Professor Halazonetis and prepared as previously described.\(^\text{48}\)

**Cellular assays.** Bioluminescence Resonance Energy Transfer assays were performed as described previously.\(^\text{33}\) Briefly, the indicated cells were seeded on 12 plates and transfected with 50 ng/well of pLRuc-BAX vector (BRET donor, BAX fused to luciferase), and increasing amount (for saturation curves), or 200 ng/well (for dose-response curves), of pYeFP-BCL-xL vector (BRET acceptor, BCL-xL fused to eYFP). Twenty-four hours later, cells were reseded into white 96-well plate and treated as indicated. Light emissions at 485 and 530 nm were measured consecutively by using the Mithras fluorescence-luminescence detector LB-940 (Berthold, Thriony, France) after addition of 5 μM of the luciferase substrate (coelenterazine H\(^\text{′}\) at 37 °C. Cells were then washed and mounted in ProLong Gold antifade reagent (Invitrogen).

**Immunoblot and antibodies.** After two washings with cold PBS, cells were lysed in ice-cold lysis buffer (SDS 1%, EDTA 10 mM, Tris-HCl pH 5.0, 50 mM protease inhibitors, Na3VO4 1 mM, NaF 100 ×) and extracts were sonicated. Protein extracts were separated by SDS-PAGE, transferred onto a PVDF membrane (Millipore, Billerica, MA, USA) and revealed with a chemiluminescence kit (Millipore). Presented Western-Blot are representative of three independent experiments. Following antibodies were used: actin (MAB1501R, Millipore), β-tubulin (T0198, Sigma), BAX (A3333, Dako), BCL-xL (1018-1, Epitomics), cytochrome c (BD-Pharmlingen San Diego, CA, USA), MCL-1 (sc-819, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), NOKA (ALX-804-408, Enzo Life Science, New York, NY, USA), PUMA (12450, Cell Signalling), p21 (2947, Cell Signalling), p53 (554294, BD-Pharmlingen). The above antibodies against BAX, BCL-xL and p53 were also used for immunoprecipitations, as those against BAX (5′-TCCCTGAAAAGTTCCAGCA/CCCTCTTGGTGAGGTCAA TG-3′) and BCL-xL (5′-GAATACAGCTGAGATCAGG-3′) were pre pared as previously described.\(^\text{48}\) The recombinant p53 was kindly provided by Professor Halazonetis and prepared as previously described.\(^\text{48}\)

**Protein extracts were separated by SDS-PAGE, transferred onto a PVDF membrane (Millipore, Billerica, MA, USA) and revealed with a chemiluminescence kit (Millipore). Presented Western-Blot are representative of three independent experiments. Following antibodies were used: actin (MAB1501R, Millipore), β-tubulin (T0198, Sigma), BAX (A3333, Dako), BCL-xL (1018-1, Epitomics), cytochrome c (BD-Pharmlingen San Diego, CA, USA), MCL-1 (sc-819, Santa Cruz Biotechnologies, Santa Cruz, CA, USA), NOKA (ALX-804-408, Enzo Life Science, New York, NY, USA), PUMA (12450, Cell Signalling), p21 (2947, Cell Signalling), p53 (554294, BD-Pharmlingen). The above antibodies against BAX, BCL-xL and p53 were also used for immunoprecipitations, as those against BAX 6A7 (ab5714, Abcam, Cambridge, UK) and FLAG-tag (F1884, Sigma).

**Quantitative PCR.** Total RNA were extracted from cells using a kit Nucleosip RNA (Macherey-Nagel, Düren, Germany) following the manufacturer instructions. Retrotranscription was performed from 500 ng RNA using Maxima First strand cDNA Synthesis kit for RTqPCR (Fisher Scientific, Pittsburgh, PA, USA). Quantitative PCR was performed with EuroBioGreen qPCR Mix Lo-ROX (Eurobio, Courtaboeuf, France) from 4 ng of retrotranscribed RNA using a Stratagene MX3005P (Agilent, Santa Clara, CA, USA). Data were analyzed using Pfaffl method with three references genes (Actb, RPLP0 and RPS18)\(^\text{47}\) and presented in mRNA levels relative to untreated cells.

**Data analysis.** Data were from three independent experiments. Unless otherwise stated, statistical analysis of data was performed using two-ways ANOVA with Bonferroni post-test on GraphPad Prism (La Jolla, CA, USA). Error bars represent S.E.Ms. The following symbols are used: *, ** and *** that correspond to a P-value inferior to 0.05, 0.01 and 0.001, respectively.

**Conflict of Interest**

The authors declare no conflict of interest.

---

\(\text{p53} \) **heightens mitochondrial apoptotic priming to favor cell death**

J Le Pen et al

*Cell Death and Disease*
Acknowledgements. We thank members of the ‘Cell Survival and Tumor Escape in Breast Cancer’ laboratory for their technical advice, fruitful comments and enthusiasm. We thank Thanos Halazonetis for his kind sharing of the p53 (79–393) construct. We thank Cécile Couriaud for her technical help in the preparation of lentivirus particles. We thank Philippe Hulin for his technical support at the Cellular and Tissular Imaging Core Facility of Nantes University (MicroPICell). JLP and CV are supported by grants from INSERM Region and the Ministère de la Recherche et de l’Enseignement Supérieur respectively. This work was supported by Région Pays de la Loire (CIMATHE), Ligue contre le Cancer (R13137) and ARC (R15093NN).

1. Lowe SW, Cepko E, Evan G. Intrinsic tumour suppression. Nature 2004; 432: 307–315.
2. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T, Green DR. Mechanism of apoptosis induction by inhibition of the anti-apoptotic Bcl-2 proteins. Proc Natl Acad Sci USA 2010; 107: 18502–18507.
3. Martinou JC, Youle RJ. Mitochondria in apoptosis: Bcl-2 family members and mitochondrial dynamics. Dev Cell 2011; 21: 92–101.
4. Tait SWG, Green DR. Cell survival in tough times: The mitochondrial recovery plan. Cell Cycle 2010; 9: 4254–4255.
5. Lalier L, Cartron PF, Juin P, Nedelkina S, Manon S, Bechinger B. Structural changes in BAK promote apoptosis. Nat Struct Mol Biol 2011; 18: 859–866.
6. Leber B, Lin J, Andrews DW. BH3-only proteins: antagonists of apoptosis. Biochim Biophys Acta 2013; 1833: 598–592.
7. Gauthier F, Guillemin Y, Carton PF, Gallenne T, Cauquil N, Le Diguercher T et al. Bax activation by engagement with, then release from, the Bcl-2 binding site of bcl-xL. Mol Cell Biol 2010; 30: 239–240.
8. Leber B, Lin J, Andrews DW. Still embedded together binding to membranes regulates Bcl-2 protein interactions. Oncogene 2010; 29: 9221–9230.
9. Czabotar PE, Westphal D, Dewson G, Ma S, Hockings C, Fairlie WD et al. BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 2009; 185: 279–290.
10. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O et al. Bax activation by the Bcl-2-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 2009; 185: 279–290.
11. Chipuk JE, Maurer U, Green DR, Schuler M. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Cancer Res 2010; 70: 9421–9430.
12. Haupt Y, Rowan S, Shaulian E, Kazaz A, Vousden K, Oren M. p53 mediated apoptosis in HeLa cells: transcription dependent and independent mechanisms. Leukemia 1997; 11 (Suppl 3): 337–339.
13. Niermeijer M, Easaline VM, Haikala HM, Vormolen JT, van der Parten J et al. Myc-induced AMPK-phospho p53 pathway activates Bax to sensitize mitochondrial apoptosis. Proc Natl Acad Sci USA 2013; 110: E1839–E1848.
14. Peitsch EC, Perchiniek E, Canutescu AA, Wang G, Dunbrack RL, Murphy ME. Oligomerization of BAX by p53 utilizes conserved residues of the p53 DNA binding domain. J Biol Chem 2008; 283: 21294–21304.
15. Nieminen AI, Eskelinen VM, Haikala HM, Vormolen JT, van der Parten J et al. Myc-induced mitochondrial apoptosis strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160: 977–989.
16. Montoro J, Sarosiak KA, DeAngelo JD, Maertens O, Ryan J, Ercan D et al. Drug-induced death signaling strategy rapidly predicts cancer response to chemotherapy. Cell 2015; 160: 977–989.